Literature DB >> 34277100

Could patients benefit from whole-brain radiotherapy with unilateral hippocampus sparing?

Lucas Gomes Sapienza1, Michelle S Ludwig1, Jacob J Mandel2, Dung H Nguyen1, Alfredo Enrique Echeverria1.   

Abstract

Entities:  

Keywords:  brain metastasis; hippocampus; neuro-cognitive function; radiotherapy

Year:  2021        PMID: 34277100      PMCID: PMC8281911          DOI: 10.5603/RPOR.a2021.0059

Source DB:  PubMed          Journal:  Rep Pract Oncol Radiother        ISSN: 1507-1367


× No keyword cloud information.
Evidence that the hippocampus plays an important role in advanced neuro-cognitive functions (NCF), including the formation of new memories, has accumulated since the 1950s [1]. Reports describing bilateral lesions in the hippocampus that developed clinically detectable neurological impairments suggest that bilateral damage of this structure have negative effects [2-3]. Recently, the randomized NRG-CC001 study [4] provided additional evidence that this structure is related to the memory functions of the brain. The authors found that in the setting of whole brain irradiation (WBRT) with memantine, lowering the bilateral hippocampal radiation dose preserved NCF and patient-reported symptoms. Importantly, relapses in the hippocampus avoidance (HA) region did not increase — occurring in 11 of 257 patients in the HA-WBRT plus memantine arm versus 16 of 261 in the WBRT plus memantine arm. In both scenarios, bilateral hippocampus alteration (damage or protection) resulted in detectable effect on NCF (impairment or preservation, respectively). An intriguing subsequent question that arises is if the integrity of both hippocampi is a necessary condition for normal — or partially normal — NCF. The implications of this question for the treatment of brain metastases with irradiation are numerous. If the hippocampus works as a serial organ (similar to spinal cord), bilateral hippocampal sparing would be necessary to preserve function. On the other hand, if the hippocampus behaves as a parallel organ (similar to the lung or the motor cortex of the brain), the avoidance of one side could result in at least partial neuro-cognitive benefit. The latter scenario would expand the indications for hippocampus avoidance because it would include patients with unilateral hippocampus metastasis that are generally not considered candidates for hippocampal preservation. In the third possibility, in which only one specific side is responsible for the function based on dominance [5, 6] (e.g. the Broca’s area responsible for the speech production), the hippocampal sparing could be unilateral instead of bilateral. In order to generate clinical data to help answer this question, it is important to routinely document dose to each hippocampi — including incidental dose from focal treatments [7] — and to determine dominant hemisphere for each particular patient. Unilateral avoidance is technically feasible with modern radiotherapy modalities [8-9]. As an illustrative example, Figure 1A–D presents WBRT plans with and without hippocampus sparing for a 62 years-old female with multiple brain metastases (eight) from high-grade serous carcinoma of the ovary. After reviewing the thin slice MRI (1 mm–1 mm), one lesion was close to the right hippocampus, but no lesions were near the left hippocampus. If WBRT is indicated, the lesion near the right hippocampus would need to be included. However, could the left hippocampus be avoided? Sparing of the left side could potentially preserve NCF if the hippocampus is considered a parallel organ or if the left side is dominant.
Figure 1

Axial and coronal views of 3D conformal WBRT plan without hippocampus sparing (A, B) and volumetric modulated arc therapy (VMAT) plan with unilateral hippocampus sparing (C, D). Red: 30 Gy isodose. Dark blue: 15 Gy isodose. Cyan: right temporal lobe metastasis. Yellow: right hippocampus. White: right hippocampus + 5 mm. Light green: left hippocampus. Dark Green: left hippocampus + 5mm. Left hippocampus D100% 8.5 Gy (target ≤ 9 Gy) and Dmax 14.4 Gy (target ≤ 16 Gy)

The exact working mechanism of the hippocampus is an intriguing and motivating area of translational research. Further investigation is necessary in determining the impacts of radiation on this bilateral organ, and whether patients with unilateral involvement of the hippocampus may be considered candidates for contralateral preservation.
  9 in total

1.  Loss of recent memory after bilateral hippocampal lesions.

Authors:  W B SCOVILLE; B MILNER
Journal:  J Neurol Neurosurg Psychiatry       Date:  1957-02       Impact factor: 10.154

2.  Severe amnesia following bilateral medial temporal lobe damage occurring on two distinct occasions.

Authors:  G Di Gennaro; L G Grammaldo; P P Quarato; V Esposito; A Mascia; A Sparano; G N Meldolesi; A Picardi
Journal:  Neurol Sci       Date:  2006-06       Impact factor: 3.307

3.  Hippocampal dose during Linac-based stereotactic radiotherapy for brain metastases: An observational study.

Authors:  Alba Fiorentino; Umberto Tebano; Gianluisa Sicignano; Francesco Ricchetti; Gioacchino Di Paola; Dario Aiello; Niccolò Giaj-Levra; Rosario Mazzola; Sergio Fersino; Ruggero Ruggieri; Filippo Alongi
Journal:  Phys Med       Date:  2017-09-23       Impact factor: 2.685

4.  Left hippocampus sparing whole brain radiotherapy (WBRT): A planning study.

Authors:  Tomas Kazda; Miroslav Vrzal; Tomas Prochazka; Petr Dvoracek; Petr Burkon; Petr Pospisil; Adam Dziacky; Tomas Nikl; Radim Jancalek; Pavel Slampa; Radek Lakomy
Journal:  Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub       Date:  2017-07-20       Impact factor: 1.245

5.  Post-WBRT cognitive impairment and hippocampal neuronal depletion measured by in vivo metabolic MR spectroscopy: Results of prospective investigational study.

Authors:  Petr Pospisil; Tomas Kazda; Ludmila Hynkova; Martin Bulik; Marie Dobiaskova; Petr Burkon; Nadia N Laack; Pavel Slampa; Radim Jancalek
Journal:  Radiother Oncol       Date:  2017-01-04       Impact factor: 6.280

6.  Hippocampal radiotherapy dose constraints for predicting long-term neurocognitive outcomes: mature data from a prospective trial in young patients with brain tumors.

Authors:  Jayant S Goda; Debnarayan Dutta; Uday Krishna; Savita Goswami; Vikas Kothavade; Sadhna Kannan; Madan Maitre; Nazia Bano; Tejpal Gupta; Rakesh Jalali
Journal:  Neuro Oncol       Date:  2020-11-26       Impact factor: 12.300

7.  Human amnesia and the medial temporal region: enduring memory impairment following a bilateral lesion limited to field CA1 of the hippocampus.

Authors:  S Zola-Morgan; L R Squire; D G Amaral
Journal:  J Neurosci       Date:  1986-10       Impact factor: 6.167

8.  Whole brain radiotherapy with hippocampal avoidance and simultaneous integrated boost for brain metastases: a dosimetric volumetric-modulated arc therapy study.

Authors:  Niccolò Giaj Levra; Gianluisa Sicignano; Alba Fiorentino; Sergio Fersino; Francesco Ricchetti; Rosario Mazzola; Stefania Naccarato; Ruggero Ruggieri; Filippo Alongi
Journal:  Radiol Med       Date:  2015-08-01       Impact factor: 3.469

9.  Hippocampal Avoidance During Whole-Brain Radiotherapy Plus Memantine for Patients With Brain Metastases: Phase III Trial NRG Oncology CC001.

Authors:  Paul D Brown; Vinai Gondi; Stephanie Pugh; Wolfgang A Tome; Jeffrey S Wefel; Terri S Armstrong; Joseph A Bovi; Cliff Robinson; Andre Konski; Deepak Khuntia; David Grosshans; Tammie L S Benzinger; Deborah Bruner; Mark R Gilbert; David Roberge; Vijayananda Kundapur; Kiran Devisetty; Sunjay Shah; Kenneth Usuki; Bethany Marie Anderson; Baldassarre Stea; Harold Yoon; Jing Li; Nadia N Laack; Tim J Kruser; Steven J Chmura; Wenyin Shi; Snehal Deshmukh; Minesh P Mehta; Lisa A Kachnic
Journal:  J Clin Oncol       Date:  2020-02-14       Impact factor: 50.717

  9 in total
  1 in total

Review 1.  Actual, Personalized Approaches to Preserve Cognitive Functions in Brain Metastases Breast Cancer Patients.

Authors:  Monika Konopka-Filippow; Dominika Hempel; Ewa Sierko
Journal:  Cancers (Basel)       Date:  2022-06-25       Impact factor: 6.575

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.